Cellectar Biosciences Inc (CLRB)

[Sluicebox]

Some highlight from the paragraph about CLR-131.
CLR-131 exploit the altered lipid composition of cancer cell membranes to more actively target tumors and deliver the radioactive payload into the cancer cell.
Advantages of this system include the PDCs’ ability to gain entry into a wide variety of cancer types and indiscriminately target all cells within a tumor without relying on expression of a specific antigen.
Furthermore, this technology could offer considerable flexibility in the types of payloads that can be used.
Cellectar has several other PDCs in preclinical development.
CLR 131 could be the first of many such drugs from Cellectar, with other payloads being explored.